{
    "id": 20810,
    "fullName": "AGAP3 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "AGAP3-BRAF results from the fusion of AGAP3 and BRAF, which leads to activation of MAPK signaling and transformation of cultured cells (PMID: 30279230, PMID: 28539463), and has been demonstrated to confer resistance to Braf inhibitors (PMID: 28539463). AGAP3-BRAF has been identified in MSI-high colorectal cancer (PMID: 30279230) and melanoma (PMID: 28539463).",
            "references": [
                {
                    "id": 13140,
                    "pubMedId": 30279230,
                    "title": "Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30279230"
                },
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 116988,
        "geneSymbol": "AGAP3",
        "terms": [
            "AGAP3",
            "AGAP-3",
            "CENTG3",
            "cnt-g3",
            "CRAG",
            "MRIP-1"
        ]
    },
    "variant": "AGAP3 - BRAF",
    "createDate": "04/07/2016",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AGAP3-BRAF in melanoma cells harboring BRAF V600E conferred resistance to PLX4720-induced inhibition of MAPK signaling and growth in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited MAPK signaling and growth of melanoma cells harboring BRAF V600E and expressing AGAP3-BRAF in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18847,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in disease progression within 2 months in a patient with melanoma harboring BRAF V600E and an acquired AGAP3-BRAF fusion (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11958,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AGAP3-BRAF in melanoma cells harboring BRAF V600E resulted in reduced response to Mekinist (trametinib) at high concentration compared to cells harboring V600E alone in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11955,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquisition of an AGAP3-BRAF fusion was identified in a melanoma patient harboring BRAF V600E who developed resistance to Zelboraf (vemurafenib), and expression of AGAP3-BRAF in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21309,
            "profileName": "AGAP3 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28367,
            "profileName": "AGAP3 - BRAF BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}